These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 32145382)

  • 1. Factors influencing safety and efficacy of intravenous iron-carbohydrate nanomedicines: From production to clinical practice.
    Nikravesh N; Borchard G; Hofmann H; Philipp E; Flühmann B; Wick P
    Nanomedicine; 2020 Jun; 26():102178. PubMed ID: 32145382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Critical nanomaterial attributes of iron-carbohydrate nanoparticles: Leveraging orthogonal methods to resolve the 3-dimensional structure.
    Krupnik L; Joshi P; Kappler A; Flühmann B; Alston AB; Digigow R; Wick P; Neels A
    Eur J Pharm Sci; 2023 Sep; 188():106521. PubMed ID: 37423578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Putting square pegs in round holes: Why traditional pharmacokinetic principles cannot universally be applied to iron-carbohydrate complexes.
    Alston AB; Digigow R; Flühmann B; Wacker MG
    Eur J Pharm Biopharm; 2023 Jul; 188():6-14. PubMed ID: 37142131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Criticality of Surface Characteristics of Intravenous Iron-Carbohydrate Nanoparticle Complexes: Implications for Pharmacokinetics and Pharmacodynamics.
    Funk F; Flühmann B; Barton AE
    Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the Physicochemical Properties of the Iron Nanoparticle Drug Products: Brand and Generic Sodium Ferric Gluconate.
    Brandis JEP; Kihn KC; Taraban MB; Schnorr J; Confer AM; Batelu S; Sun D; Rodriguez JD; Jiang W; Goldberg DP; Langguth P; Stemmler TL; Yu YB; Kane MA; Polli JE; Michel SLJ
    Mol Pharm; 2021 Apr; 18(4):1544-1557. PubMed ID: 33621099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Snapshots of Iron Speciation: Tracking the Fate of Iron Nanoparticle Drugs via a Liquid Chromatography-Inductively Coupled Plasma-Mass Spectrometric Approach.
    Neu HM; Alexishin SA; Brandis JEP; Williams AMC; Li W; Sun D; Zheng N; Jiang W; Zimrin A; Fink JC; Polli JE; Kane MA; Michel SLJ
    Mol Pharm; 2019 Mar; 16(3):1272-1281. PubMed ID: 30676753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complexity of intravenous iron nanoparticle formulations: implications for bioequivalence evaluation.
    Pai AB
    Ann N Y Acad Sci; 2017 Nov; 1407(1):17-25. PubMed ID: 29027212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iron Treatment Strategies in Dialysis-Dependent CKD.
    Pandey R; Daloul R; Coyne DW
    Semin Nephrol; 2016 Mar; 36(2):105-11. PubMed ID: 27236131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The intravenous use of high molecular ferric carbohydrate compound in the treatment of hypochromic anemia.
    LUCAS JE; HAGEDORN AB
    Blood; 1952 Mar; 7(3):358-67. PubMed ID: 14904518
    [No Abstract]   [Full Text] [Related]  

  • 10. Nanomedicines in clinical practice: Are colloidal iron sucrose ready-to-use intravenous solutions interchangeable?
    Di Francesco T; Sublet E; Borchard G
    Eur J Pharm Sci; 2019 Apr; 131():69-74. PubMed ID: 30742979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Balance of Benefit and Risk in Intravenous Iron Treatment in Chronic Kidney Disease.
    Fishbane S
    Semin Nephrol; 2016 Mar; 36(2):119-23. PubMed ID: 27236133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences between intravenous iron products: focus on treatment of iron deficiency in chronic heart failure patients.
    Martin-Malo A; Borchard G; Flühmann B; Mori C; Silverberg D; Jankowska EA
    ESC Heart Fail; 2019 Apr; 6(2):241-253. PubMed ID: 30694615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous Iron-Carbohydrate Nanoparticles and Their Similars. What Do We Choose?
    Mehedinti AM; Capusa C; Andreiana I; Mircescu G
    Maedica (Bucur); 2022 Jun; 17(2):436-448. PubMed ID: 36032600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New insights into iron deficiency and iron deficiency anemia.
    Camaschella C
    Blood Rev; 2017 Jul; 31(4):225-233. PubMed ID: 28216263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The safety of available treatment options for iron-deficiency anemia.
    Muñoz M; Gómez-Ramírez S; Bhandari S
    Expert Opin Drug Saf; 2018 Feb; 17(2):149-159. PubMed ID: 29103332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iron polymaltose complexes: Could we spot physicochemical differences in medicines sharing the same active pharmaceutical ingredient?
    Di Francesco T; Delafontaine L; Philipp E; Lechat E; Borchard G
    Eur J Pharm Sci; 2020 Feb; 143():105180. PubMed ID: 31841697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulatory challenges and approaches to characterize nanomedicines and their follow-on similars.
    Mühlebach S; Borchard G; Yildiz S
    Nanomedicine (Lond); 2015 Mar; 10(4):659-74. PubMed ID: 25723097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Core size determination and structural characterization of intravenous iron complexes by cryogenic transmission electron microscopy.
    Wu Y; Petrochenko P; Chen L; Wong SY; Absar M; Choi S; Zheng J
    Int J Pharm; 2016 May; 505(1-2):167-74. PubMed ID: 27001529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of intravenous iron administration for uterine bleeding or postpartum anaemia: a narrative review.
    Daniilidis A; Panteleris N; Vlachaki E; Breymann C; Assimakopoulos E
    J Obstet Gynaecol; 2018 May; 38(4):443-447. PubMed ID: 29057687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnosis and treatment of unexplained anemia with iron deficiency without overt bleeding.
    Dahlerup JF; Eivindson M; Jacobsen BA; Jensen NM; Jørgensen SP; Laursen SB; Rasmussen M; Nathan T
    Dan Med J; 2015 Apr; 62(4):C5072. PubMed ID: 25872536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.